AIDEA Tech Challenge - AI in Diagnostics for Equity & Access

AIDEA Tech Challenge co-led by ADB and PATH is a global call for AI based screening and diagnostics innovations that align with the WHO Essential Diagnostic List (WHO EDL), Priority Disease List and Priority Bacterial Pathogen List, as well as, with the national priorities of countries in Asia and Pacific.

chevron_leftMore
Previous
Morechevron_right
Next

Eligibility

 

Affordable technology innovations with feasibility of implementation in the real-world scenarios of low-resource settings.

 

 

Innovations in priority focus areas that are at TRL 7 or above (i.e., Actual system prototype is ready and has been demonstrated in an operational environment or is at pilot level) based on the validation data, economic effectiveness, feasibility, scalability, and impact.

 

 

Innovations with potential for impact through advancing access to diagnostics in Asia Pacific, and with scalability potential across populations or geographies.

 

SELECTION CRITERIA

The projects will be assessed following the criteria below. Each of the criterion will be graded using scale from 1 to 10 (10=Excellent, 1=Poor). The weights of the scores (as percentages) for each criterion are indicated in the criterion headers.

  • Product Stage (20%) - The stage of the technology as per the technology readiness levels defined. We are looking for TRL 8 or plus level innovative solutions applied in their final form and are operational. Refer to TRL description for more details.

  • Evidence-Based Validation (20%) - The technology will be reviewed for clinical correlation of AI based results with validation data. Published data will be given more weightage.

  • Operational Scalability (20%) - The technology will be evaluated on its performance data from real-world deployments (pilot or large scale). Existing deployments, their effectiveness study, or the feasibility assessment (if done).

  • Innovativeness (10%) - The viability and feasibility of the technological solution from a technical, economic, and social context to be scaled-up. The extent to which the proposed budget is realistic, within scope, and accounts for unknown challenges. The feasibility of implementing the solution at scale.

  • Usability, Acceptability & Equity (10%) -The technology will be evaluated on its end-user and healthcare acceptance programmatic fit for LMICs, and its potential to address or migrate health inequities, including affordability and accessibility for low-income and vulnerable population.

  • Market Introduction Roadmap (10%) - Assessment of the market entry plan, key strategic ideas on market introduction, commercialization, including plans to navigate the necessary regulatory approvals.

  • Team (10%) - The technology will also be evaluated on the core team capabilities, strength and complementarities.

 
Participate